Alcon Inc (ALC)
80.76
+0.15
(+0.19%)
USD |
NYSE |
Apr 23, 16:00
80.76
0.00 (0.00%)
Pre-Market: 20:00
Alcon Cash from Financing (TTM)
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2022 | -8.00M |
| September 30, 2022 | -322.00M |
| June 30, 2022 | -324.00M |
| March 31, 2022 | -209.00M |
| December 31, 2021 | -123.00M |
| September 30, 2021 | -147.00M |
| June 30, 2021 | -245.00M |
| Date | Value |
|---|---|
| March 31, 2021 | 445.00M |
| December 31, 2020 | 466.00M |
| September 30, 2020 | 479.00M |
| June 30, 2020 | 547.00M |
| March 31, 2020 | 12.00M |
| December 31, 2019 | 659.00M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-324.00M
Minimum
Jun 2022
659.00M
Maximum
Dec 2019
94.62M
Average
-8.00M
Median
Dec 2022
Cash from Financing (TTM) Benchmarks
| AC Immune SA | 48.17M |
| CRISPR Therapeutics AG | 62.66M |
| Addex Therapeutics Ltd | 5.863M |
| NLS Pharmaceutics Ltd | 13.81M |
| Molecular Partners AG | -1.300M |